“…Eryptosis has been observed in a wide variety of further anemic conditions, including sickle-cell anemia [59,60], beta-thalassemia [55], glucose-6-phosphate dehydrogenase (G6PD)-deficiency [55], phosphate depletion [59], iron deficiency [61], Hemolytic Uremic Syndrome [62], sepsis [63], malaria [64] and Wilson disease [35]. Moreover, enhanced eryptosis could contribute to the anemia following excessive formation, treatment or intoxication with hemolysin Kanagawa [65], listeriolysin [66], PGE 2 [67], lipoxygenase inhibitor Bay-5884 [68], platelet activating factor [69], paclitaxel [70], methylglyoxal [71], chlorpromazine [72], amantadine [73], cyclosporine [34], curcumin [74], amyloid peptides [75], aluminium [34], lead [32], mercury [33] and copper ions [35]. …”